Quarterly ResultMay 7, 2026, 04:40 PM
BridgeBio Q1 Net Product Revenue +392% to $180.6M; NDA Submitted
AI Summary
BridgeBio Pharma reported a significant increase in net product revenue for Q1 2026, driven by the commercial success of Attruby/Beyonttra. The company also submitted a New Drug Application to the FDA for BBP-418 for LGMD2I/R9, highlighting progress in its late-stage pipeline. Despite increased operating expenses, the net loss slightly improved compared to the prior year, supported by strong revenue growth and financing activities.
Key Highlights
- Submitted New Drug Application to FDA for oral BBP-418 for LGMD2I/R9 on March 30, 2026.
- Net product revenue surged 392% to $180.6 million in Q1 2026 from $36.7 million in Q1 2025.
- Total revenues increased 67% to $194.5 million in Q1 2026 from $116.6 million in Q1 2025.
- Net loss attributable to common stockholders improved to $(164.0) million from $(167.4) million.
- Net loss per share improved to $(0.84) from $(0.88) year-over-year.
- Cash and cash equivalents increased to $879.9 million as of March 31, 2026.
- Issued $632.5 million in 2033 Notes; repurchased $82.5 million of common stock.